Biosimilar monoclonal antibodies in Latin America

Autores
Karp, Paola Julieta; Gatto, Matías Iván; Batto, María Victoria; Ferrero, Sol; Helguera, Gustavo Fernando
Año de publicación
2021
Idioma
inglés
Tipo de recurso
parte de libro
Estado
versión publicada
Descripción
Antibodies, also known as immunoglobulins, are complex glycoproteins produced by B-cells against foreign substances as part of the adaptive immune response [1, 2]. The invention of the hybridoma technology in 1975 by Köhler and Milstein allowed the production of monoclonal antibodies with a desired specificity from a unique clone of B cells [3]. In contrast to polyclonal antibodies, monoclonal antibodies are homogeneous, monospecific, and could be produced in unlimited quantities in the laboratory. Since they can be directed against almost any molecular epitope, monoclonal antibodies were early adopted as a diagnostic tool, but took more than a decade until the approval of Muromonab-CD3 (Orthoclone Okt3®), which is the first monoclonal antibody developed with the hybridoma technology commercialized for therapeutic use [4]. However, since antibodies from hybridoma technology have only murine sequences, in human patients they exhibited limited effector function [5], were immunogenic inducing anti-mouse antibodies, and had a significantly reduced half-life [6]. Therefore, it was not until the development of recombinant monoclonal antibodies in the 1980s and 1990s that a new era of biologic therapy began, with the chimerical [7], humanized [8] and fully human antibodies [9]. Each step involved the gradual replacement of murine segments of the antibody sequence by the corresponding human sequence: in chimeric antibodies the constant region was replaced, and in humanized antibodies, the framework flanking the complementarity-determining regions and the constant region were replaced, and in human monoclonal antibodies the whole sequence is human. Further engineering allowed their customization, creating variants in valence, size, effector functions and with the conjugation of compounds for delivery to targeted cell types such as cancer.
Fil: Karp, Paola Julieta. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Gatto, Matías Iván. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Batto, María Victoria. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Ferrero, Sol. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Helguera, Gustavo Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Materia
MONOCLONAL ANTIBODY
BIOSIMILAR
BIOLOGICS
LATIN AMERICA
ARGENTINA
BRASIL
CHILE
MEXICO
PERU
COLOMBIA
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/166193
Acceder
id CONICETDig_13a1cb8334e1c554c18ccda93a88a529
oai_identifier_str oai:ri.conicet.gov.ar:11336/166193
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Biosimilar monoclonal antibodies in Latin AmericaKarp, Paola JulietaGatto, Matías IvánBatto, María VictoriaFerrero, SolHelguera, Gustavo FernandoMONOCLONAL ANTIBODYBIOSIMILARBIOLOGICSLATIN AMERICAARGENTINABRASILCHILEMEXICOPERUCOLOMBIAhttps://purl.org/becyt/ford/3.4https://purl.org/becyt/ford/3Antibodies, also known as immunoglobulins, are complex glycoproteins produced by B-cells against foreign substances as part of the adaptive immune response [1, 2]. The invention of the hybridoma technology in 1975 by Köhler and Milstein allowed the production of monoclonal antibodies with a desired specificity from a unique clone of B cells [3]. In contrast to polyclonal antibodies, monoclonal antibodies are homogeneous, monospecific, and could be produced in unlimited quantities in the laboratory. Since they can be directed against almost any molecular epitope, monoclonal antibodies were early adopted as a diagnostic tool, but took more than a decade until the approval of Muromonab-CD3 (Orthoclone Okt3®), which is the first monoclonal antibody developed with the hybridoma technology commercialized for therapeutic use [4]. However, since antibodies from hybridoma technology have only murine sequences, in human patients they exhibited limited effector function [5], were immunogenic inducing anti-mouse antibodies, and had a significantly reduced half-life [6]. Therefore, it was not until the development of recombinant monoclonal antibodies in the 1980s and 1990s that a new era of biologic therapy began, with the chimerical [7], humanized [8] and fully human antibodies [9]. Each step involved the gradual replacement of murine segments of the antibody sequence by the corresponding human sequence: in chimeric antibodies the constant region was replaced, and in humanized antibodies, the framework flanking the complementarity-determining regions and the constant region were replaced, and in human monoclonal antibodies the whole sequence is human. Further engineering allowed their customization, creating variants in valence, size, effector functions and with the conjugation of compounds for delivery to targeted cell types such as cancer.Fil: Karp, Paola Julieta. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Gatto, Matías Iván. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Batto, María Victoria. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Ferrero, Sol. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Helguera, Gustavo Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaIntechOpenFeijó Azevedo, ValderilioMoots, Robert2021info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/bookParthttp://purl.org/coar/resource_type/c_3248info:ar-repo/semantics/parteDeLibroapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/166193Karp, Paola Julieta; Gatto, Matías Iván; Batto, María Victoria; Ferrero, Sol; Helguera, Gustavo Fernando; Biosimilar monoclonal antibodies in Latin America; IntechOpen; 2021; 1-27978-1-83881-943-9CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.intechopen.com/chapters/79577info:eu-repo/semantics/altIdentifier/doi/10.5772/intechopen.101227info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:50:33Zoai:ri.conicet.gov.ar:11336/166193instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:50:33.309CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Biosimilar monoclonal antibodies in Latin America
title Biosimilar monoclonal antibodies in Latin America
spellingShingle Biosimilar monoclonal antibodies in Latin America
Karp, Paola Julieta
MONOCLONAL ANTIBODY
BIOSIMILAR
BIOLOGICS
LATIN AMERICA
ARGENTINA
BRASIL
CHILE
MEXICO
PERU
COLOMBIA
title_short Biosimilar monoclonal antibodies in Latin America
title_full Biosimilar monoclonal antibodies in Latin America
title_fullStr Biosimilar monoclonal antibodies in Latin America
title_full_unstemmed Biosimilar monoclonal antibodies in Latin America
title_sort Biosimilar monoclonal antibodies in Latin America
dc.creator.none.fl_str_mv Karp, Paola Julieta
Gatto, Matías Iván
Batto, María Victoria
Ferrero, Sol
Helguera, Gustavo Fernando
author Karp, Paola Julieta
author_facet Karp, Paola Julieta
Gatto, Matías Iván
Batto, María Victoria
Ferrero, Sol
Helguera, Gustavo Fernando
author_role author
author2 Gatto, Matías Iván
Batto, María Victoria
Ferrero, Sol
Helguera, Gustavo Fernando
author2_role author
author
author
author
dc.contributor.none.fl_str_mv Feijó Azevedo, Valderilio
Moots, Robert
dc.subject.none.fl_str_mv MONOCLONAL ANTIBODY
BIOSIMILAR
BIOLOGICS
LATIN AMERICA
ARGENTINA
BRASIL
CHILE
MEXICO
PERU
COLOMBIA
topic MONOCLONAL ANTIBODY
BIOSIMILAR
BIOLOGICS
LATIN AMERICA
ARGENTINA
BRASIL
CHILE
MEXICO
PERU
COLOMBIA
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.4
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Antibodies, also known as immunoglobulins, are complex glycoproteins produced by B-cells against foreign substances as part of the adaptive immune response [1, 2]. The invention of the hybridoma technology in 1975 by Köhler and Milstein allowed the production of monoclonal antibodies with a desired specificity from a unique clone of B cells [3]. In contrast to polyclonal antibodies, monoclonal antibodies are homogeneous, monospecific, and could be produced in unlimited quantities in the laboratory. Since they can be directed against almost any molecular epitope, monoclonal antibodies were early adopted as a diagnostic tool, but took more than a decade until the approval of Muromonab-CD3 (Orthoclone Okt3®), which is the first monoclonal antibody developed with the hybridoma technology commercialized for therapeutic use [4]. However, since antibodies from hybridoma technology have only murine sequences, in human patients they exhibited limited effector function [5], were immunogenic inducing anti-mouse antibodies, and had a significantly reduced half-life [6]. Therefore, it was not until the development of recombinant monoclonal antibodies in the 1980s and 1990s that a new era of biologic therapy began, with the chimerical [7], humanized [8] and fully human antibodies [9]. Each step involved the gradual replacement of murine segments of the antibody sequence by the corresponding human sequence: in chimeric antibodies the constant region was replaced, and in humanized antibodies, the framework flanking the complementarity-determining regions and the constant region were replaced, and in human monoclonal antibodies the whole sequence is human. Further engineering allowed their customization, creating variants in valence, size, effector functions and with the conjugation of compounds for delivery to targeted cell types such as cancer.
Fil: Karp, Paola Julieta. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Gatto, Matías Iván. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Batto, María Victoria. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Ferrero, Sol. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Helguera, Gustavo Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
description Antibodies, also known as immunoglobulins, are complex glycoproteins produced by B-cells against foreign substances as part of the adaptive immune response [1, 2]. The invention of the hybridoma technology in 1975 by Köhler and Milstein allowed the production of monoclonal antibodies with a desired specificity from a unique clone of B cells [3]. In contrast to polyclonal antibodies, monoclonal antibodies are homogeneous, monospecific, and could be produced in unlimited quantities in the laboratory. Since they can be directed against almost any molecular epitope, monoclonal antibodies were early adopted as a diagnostic tool, but took more than a decade until the approval of Muromonab-CD3 (Orthoclone Okt3®), which is the first monoclonal antibody developed with the hybridoma technology commercialized for therapeutic use [4]. However, since antibodies from hybridoma technology have only murine sequences, in human patients they exhibited limited effector function [5], were immunogenic inducing anti-mouse antibodies, and had a significantly reduced half-life [6]. Therefore, it was not until the development of recombinant monoclonal antibodies in the 1980s and 1990s that a new era of biologic therapy began, with the chimerical [7], humanized [8] and fully human antibodies [9]. Each step involved the gradual replacement of murine segments of the antibody sequence by the corresponding human sequence: in chimeric antibodies the constant region was replaced, and in humanized antibodies, the framework flanking the complementarity-determining regions and the constant region were replaced, and in human monoclonal antibodies the whole sequence is human. Further engineering allowed their customization, creating variants in valence, size, effector functions and with the conjugation of compounds for delivery to targeted cell types such as cancer.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/bookPart
http://purl.org/coar/resource_type/c_3248
info:ar-repo/semantics/parteDeLibro
status_str publishedVersion
format bookPart
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/166193
Karp, Paola Julieta; Gatto, Matías Iván; Batto, María Victoria; Ferrero, Sol; Helguera, Gustavo Fernando; Biosimilar monoclonal antibodies in Latin America; IntechOpen; 2021; 1-27
978-1-83881-943-9
CONICET Digital
CONICET
url http://hdl.handle.net/11336/166193
identifier_str_mv Karp, Paola Julieta; Gatto, Matías Iván; Batto, María Victoria; Ferrero, Sol; Helguera, Gustavo Fernando; Biosimilar monoclonal antibodies in Latin America; IntechOpen; 2021; 1-27
978-1-83881-943-9
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.intechopen.com/chapters/79577
info:eu-repo/semantics/altIdentifier/doi/10.5772/intechopen.101227
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv IntechOpen
publisher.none.fl_str_mv IntechOpen
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269037757726720
score 13.13397

Publicaciones similares